Showing results (21-30 of 113) with videos related to
Sort By:
Pageof 12
Health Policy (Amsterdam, Netherlands)|October 11, 2014
The impact of no-fault compensation on health care expenditures: an empirical study of OECD countriesTom Vandersteegen, Wim Marneffe, Irina Cleemput, et al.Australian Critical Care : Official Journal of the Confederation of Australian Critical Care Nurses|August 24, 2013
Infection prevention and control strategies in the era of limited resources and quality improvement: a perspective paperDominique Vandijck, Irina Cleemput, Johan Hellings, et al.Frontiers in Pharmacology|October 21, 2011
Valorising and creating access to innovative medicines in the European unionLieven Annemans, Irina Cleemput, Frank Hulstaert, et al.Journal of Comparative Effectiveness Research|November 19, 2013
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EULieven Annemans, Irina Cleemput, Frank Hulstaert, et al.International Journal of Technology Assessment in Health Care|September 18, 2012
European drug reimbursement systems' legitimacy: five-country comparison and policy toolIrina Cleemput, Margreet Franken, Marc Koopmanschap, et al.Health Policy (Amsterdam, Netherlands)|May 22, 2012
Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational dataMattias Neyt, Irina Cleemput, Nancy Thiry, et al.International Journal of Technology Assessment in Health Care|September 20, 2012
Similarities and differences between five European drug reimbursement systemsMargreet Franken, Maïté le Polain, Irina Cleemput, et al.Pharmacoeconomics|December 21, 2004
The economic implications of non-adherence after renal transplantationIrina Cleemput, Katrien Kesteloot, Yves Vanrenterghem, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 11, 2009
Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requestsIrina Cleemput, Philippe van Wilder, Michel Huybrechts, et al.Plos One|April 10, 2018
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysisMattias Neyt, Joan Vlayen, Stephan Devriese, et al.Pageof 12